Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease | Bayer | Terminated | Finerenone | 3 | BAY 94-8862 16244 | King Abdulaziz University Hospital (Jeddah) |
| "A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2" | Bayer | Terminated | BAY 80-6946/Copanlisib | 3 | BAY 80-6946 / 17322 | King Abdulaziz University Hospital (Jeddah), King Abdullah Medical City (Makkah), King Fahad Specialist Hospital (Dammam) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer | AstraZeneca | Ongoing | MEDI4736/Paclitaxel | 2 | ESR-14-10649 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) | AstraZeneca | Ongoing | MEDI4736+Tremelimumab | 3 | D419AC00003 | King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Randomized, three- way, three- period, single oral dose, open-label, crossover, bioequivalence study to compare Lorvast Tablets /Tabuk Pharmaceutical Mfg. Co. (20 mg Atorvastatin), versus Lipitor® (20 mg Atorvastatin) Produced by Pfizer in healthy subjects under fasting conditions. | SFDA | Completed | Lipitor® lovarst tablet | 4 | 42370 | saudi Ajal |
| RIFTOS MKI - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors | Bayer | Ongoing | Nexavar (Sorafenib) | 4 | 17852 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Treatment Patterns, Outcomes, and Resource Use Study For Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-Squamous)in Kingdom of Saudi Arabia and United Arab Emirates | Bristol-Myers Squibb | Ongoing | - | 4 | CA209454 | King Abdulaziz Medical City NG (Riyadh) |
| SAUDI ARABIA – A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Roche | Ongoing | N/A | 4 | ML29618 | King Abdulaziz Medical City NG (Riyadh) |
| The study of efficacy and saftey of Rituximab in treatment of resistant glomerulonephritis | The Saudi center for Organ Transplantation (SCOT) | Ongoing | Rituximab | 3 | MN-101-11 | King Fahad Medical City (Riyadh), King Abdulaziz Hospital and Oncology Center (Jeddah), Dammam Medical Complex, King Fahad Hospital (Jeddah), Armed Forces Hospital (Al-Hada), Armed Forces Hospital (Southern Region), King Fahad University Hospital (Al-Khobar), King Fahd Armed Forces Hospital (Jeddah) |
| Phase III, Double-Blind, Placebo-Controlled Study Of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With Or Without Nimotuzumab For Stage III/IV Head And Neck Squamous Cell Cancer | King Fahad Medical City | Ongoing | Nimotuzumab | 3 | 1HN01 | King Fahad Medical City (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.